Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that it has acquired the trademarks of specialty brands, Progynova® and CycloProgynova® and related assets, for India from Mercury Pharma Group Limited, a UK-headquartered specialty pharmaceutical company.

Progynova® (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis1. CycloProgynova®2 (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components3. Progynova® is the #1 Brand in the Estradiol represented pharmaceutical market (RPM)4, with strong physician equity and brand recall in India. As per IQVIA MAT December 2025, the brand recorded sales of INR 100 cr. The acquisition strengthens Dr. Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's, said: "The acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India. With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact. Furthermore, this acquisition brings a first-in-class treatment closer to patients, underscoring our commitment to innovation and patient care at the centre of everything we do."

Source : Equity Bulls

Keywords

DrReddysLaboratories RDY HormoneReplacementTherapy Acquisition